17-10400
Anti-phospho-MLKL (Ser358) Antibody Set
from rabbit, purified by affinity chromatography
Sign Into View Organizational & Contract Pricing
All Photos(2)
Mixed lineage kinase domain-like protein, MLKL
Recommended Products
biological source
rabbit
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human
technique(s)
western blot: suitable
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer358)
Gene Information
human ... MLKL(197259)
General description
Mixed lineage kinase domain-like protein (MLKL) is required for the execution of programmed necrosis. MLKL is a cell-permeable acrylamide compound that inhibits human, but not murine, MLKL adaptor function via covalent modification of Cys86. MLKL prevents the MLKL-RIP1-RIP3 necrosome complex from interacting with further downstream effectors.
This phospho-MLKL (Ser358) antibody set contains one vial of phospho-MLKL (Ser358) antibody and one vial of MLKL “Total” antibody.
RECOMMENDED USAGE:
It is recommended to first perform immunoprecipitation on your sample using the non-phosphorylated MLKL antibody for “total” MLKL protein isolation (see protocol section on page 2 of the Certificate of Analysis); then use the immunoprecipitated sample to detect the phosphorylated protein using the phospho-MLKL (Ser358) antibody via western blot.
RECOMMENDED USAGE:
It is recommended to first perform immunoprecipitation on your sample using the non-phosphorylated MLKL antibody for “total” MLKL protein isolation (see protocol section on page 2 of the Certificate of Analysis); then use the immunoprecipitated sample to detect the phosphorylated protein using the phospho-MLKL (Ser358) antibody via western blot.
Specificity
When used together and under the “Recommended Usage” instructions, this antibody set will detect MLKL phosphorylated at Ser358.
Immunogen
Epitope: Ser358
Linear peptide corresponding to the Protein Kinase Domain of phospho-MLKL (Ser358).
Application
Western Blot Analysis:
Untreated HT-29 cell lysates or lysates from HT-29 cells treated with Cycloheximide,Z-VAD-FMK and TNF alpha were first immunoprecipitated using the Anti-MLKL “total” antibody (1:1000 dilution) to isolate the MLKL protein.
The isolated “total” MLKL protein sample was then probed with Anti-phospho-MLKL (Ser358) (1:1000 dilution).
Untreated HT-29 cell lysates or lysates from HT-29 cells treated with Cycloheximide,Z-VAD-FMK and TNF alpha were first immunoprecipitated using the Anti-MLKL “total” antibody (1:1000 dilution) to isolate the MLKL protein.
The isolated “total” MLKL protein sample was then probed with Anti-phospho-MLKL (Ser358) (1:1000 dilution).
Anti-phospho-MLKL (Ser358) Antibody Set is an antibody set against phospho-MLKL (Ser358) for use in WB.
Components
One vial of phospho-MLKL (Ser358) antibody
One vial of MLKL “Total” antibody
One vial of MLKL “Total” antibody
Quality
Anti- MLKL (Total Antibody): Evaluated by Immunoprecipitation on HT-29 cell lysates.
Anti-phospho-MLKL (Ser358) Antibody: Evaluated by Dot Blot on phosphorylated and non-phosphorylated MLKL peptides.
Anti-phospho-MLKL (Ser358) Antibody: Evaluated by Dot Blot on phosphorylated and non-phosphorylated MLKL peptides.
Target description
~54 kDa
Physical form
100 µL of Anti-phospho-MLKL (Ser358) purified polyclonal antibody in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% sodium azide.
100 µg (concentration: 1 mg/mL) of Anti- MLKL purified polyclonal antibody in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% sodium azide.
100 µg (concentration: 1 mg/mL) of Anti- MLKL purified polyclonal antibody in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% sodium azide.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Cold Spring Harbor molecular case studies, 8(4) (2022-06-23)
Schwannomatosis is a rare genetic disorder that predisposes individuals to development of multiple schwannomas mainly in spinal and peripheral nerves and to debilitating chronic pain often unrelated to any schwannoma. Pathogenic variants of two genes, SMARCB1 and LZTR1, are causal
Nature communications, 7, 10274-10274 (2016-01-29)
Crystals cause injury in numerous disorders, and induce inflammation via the NLRP3 inflammasome, however, it remains unclear how crystals induce cell death. Here we report that crystals of calcium oxalate, monosodium urate, calcium pyrophosphate dihydrate and cystine trigger caspase-independent cell
Contraction Band Necrosis with Dephosphorylated Connexin 43 in Rat Myocardium after Daily Cocaine Administration.
International Journal of Molecular Sciences, 23 (2022)
Translational oncology, 13(2), 372-382 (2019-12-31)
The efficacy of chemotherapeutic agents in killing cancer cells is mainly attributed to the induction of apoptosis. However, the tremendous efforts on enhancing apoptosis-related mechanisms have only moderately improved lung cancer chemotherapy, suggesting that other cell death mechanisms such as
Cell death & disease, 7(6), e2287-e2287 (2016-07-01)
We previously reported that renal clear cell carcinoma cells (RCC) express both tumor necrosis factor receptor (TNFR)-1 and -2, but that, in organ culture, a TNF mutein that only engages TNFR1, but not TNFR2, causes extensive cell death. Some RCC
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service